ArticleInternational journal of surgery (London, England)2026
Integrated multi-omics identifies MCRS1 as a causal hub linking aging, metabolic syndrome, and breast cancer progression.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAging and metabolic syndrome (MetS) are intertwined risk factors for breast cancer (BC), but the core molecular nexus integrating these states is unknown. This study aimed to identify and validate a causal driver at this intersection.
methodsWe integrated transcriptomic datasets from BC, MetS, and aging cohorts to identify common dysregulated genes. Machine learning algorithms prioritized a core diagnostic signature. We used Mendelian randomization to infer causality and characterized the lead candidate using single-cell RNA sequencing and comprehensive preclinical validation.
resultsOur analysis identified a 25-gene core at the intersection of BC, MetS, and aging. Machine learning distilled this to five hub genes that formed a highly accurate diagnostic nomogram. Critically, Mendelian randomization established MCRS1 as the sole causal risk factor for BC among these candidates. Single-cell analysis revealed that Mcrs1 is predominantly expressed in proliferating cancer cells, where it drives a transcriptional program of enhanced cell cycle, senescence, and metabolic reprogramming. Accordingly, genetic knockdown of Mcrs1 profoundly suppressed BC cell proliferation and invasion in vitro, and in vivo experiments using an orthotopic BC model in C57BL/6 mice demonstrated significantly reduced tumor growth.
conclusionThis study identifies MCRS1 as a central molecular hub that causally links aging and MetS to BC pathogenesis. MCRS1 is a validated driver of tumor progression and a high-performance biomarker, representing a potential target for therapeutic development, particularly in BC patients with metabolic comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.